Switching and dose-conversion guide
WHAT THE FDA LABELS SAY · FOR DISCUSSION WITH YOUR PRESCRIBER
Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy
Important: do not use this page to change a dose. ADHD medicines that contain the same ingredient are often not interchangeable milligram for milligram, because they release the drug differently and contain different salt forms. Most labels say to stop the old medicine and adjust the new one from its starting dose. Only your prescriber can plan a switch.
In plain words
- A few labels give a direct conversion: from short-acting methylphenidate to Concerta, Relexxii or Ritalin LA; from methylphenidate to Focalin or Focalin XR (half the total daily dose; they contain dexmethylphenidate, the more active form of methylphenidate); from Adderall tablets to Adderall XR; and from Adderall XR to Adzenys XR-ODT.
- Some products can be swapped between their own forms at the same dose (for example, Vyvanse capsules and chewables, or Dyanavel XR liquid and tablets).
- Most other labels say not to swap milligram for milligram: the old medicine is stopped and the new one is adjusted step by step.
- No label converts between methylphenidate and amphetamine products, or between a stimulant and a nonstimulant.
- Talk to your prescriber before any change, and ask how to watch for side effects or loss of effect during the switch.
Methylphenidates
Concerta · Prescribing Information, revised 04/2026
If you take short-acting methylphenidate two or three times a day, the Concerta label gives a matching once-a-morning starting dose.
Label section 2.4: Starting dose for patients switching from immediate-release methylphenidate given two or three times daily (10–60 mg/day). The 72 mg dose is only for patients 13–65 years old. Adjust in 18 mg steps at weekly intervals.
| Previous immediate-release methylphenidate | Concerta starting dose |
|---|---|
| 5 mg two or three times daily | 18 mg every morning |
| 10 mg two or three times daily | 36 mg every morning |
| 15 mg two or three times daily | 54 mg every morning |
| 20 mg two or three times daily | 72 mg every morning (ages 13–65 only) |
Focalin XR · Prescribing Information, revised 09/2025
Focalin XR contains dexmethylphenidate, the more active of the two mirror-image forms that make up methylphenidate (label 12.2), and the label starts it at half your current daily methylphenidate dose.
Label section 2.2: For patients currently taking racemic methylphenidate, start Focalin XR at half (1/2) the total daily methylphenidate dose.
From Focalin tablets, the label allows the same total daily dose as Focalin XR.
Label section 2.2: Patients taking Focalin (dexmethylphenidate) immediate-release tablets may be given the same total daily dose of Focalin XR.
Jornay PM · Prescribing Information, revised 09/2025
Dose is worked out again from the start.
Label section 2.4: From other methylphenidate products: stop and titrate; do not substitute milligram-for-milligram.
Ritalin LA · Prescribing Information, revised 09/2025
If you take methylphenidate tablets twice a day, the label gives the matching once-daily capsule dose.
Label section 2.3: Conversion from Ritalin (methylphenidate hydrochloride tablets) taken twice daily to Ritalin LA once daily.
| Ritalin (methylphenidate tablets), twice daily | Ritalin LA, once daily |
|---|---|
| 5 mg | 10 mg |
| 10 mg | 20 mg |
| 15 mg | 30 mg |
| 20 mg | 40 mg |
| 30 mg | 60 mg |
From other long-acting methylphenidate products, the dose is worked out again from the start.
Label section 2.4: From other methylphenidate products: stop the old product and titrate; do not substitute milligram-for-milligram (different methylphenidate base compositions and pharmacokinetics).
Quillivant XR · Prescribing Information, revised 03/2026
Dose is worked out again from the start.
Label section 2.4: From other methylphenidate products: stop and titrate; do not substitute milligram-for-milligram.
Azstarys · Prescribing Information, revised 09/2025
Dose is worked out again from the start.
Label section 2.4: From other methylphenidate products: stop and titrate; do not substitute milligram-for-milligram.
Daytrana · Prescribing Information, revised 09/2025
Moving to the patch from a methylphenidate pill means starting at the lowest patch and adjusting.
Label section 2.2: Patients converting from another methylphenidate formulation should follow the standard titration schedule (starting at the 10 mg patch) because bioavailability differs.
Adhansia XR · Prescribing Information, revised 06/2021
Dose is worked out again from the start.
Label section 2.4: From other methylphenidate products: stop and titrate; do not substitute milligram-for-milligram.
QuilliChew ER · Prescribing Information, revised 04/2026
Dose is worked out again from the start.
Label section 2.4: From other methylphenidate products: stop and titrate; do not substitute milligram-for-milligram.
Focalin · Prescribing Information, revised 05/2024
Focalin contains dexmethylphenidate, the more active of the two mirror-image forms that make up methylphenidate (label 12.2), and the label starts it at half your current daily methylphenidate dose.
Label section 2.2: For patients currently taking racemic methylphenidate, start Focalin at half (1/2) the total daily methylphenidate dose.
Relexxii · Prescribing Information, revised 09/2025
The Relexxii label gives a once-daily starting dose for people already on methylphenidate two or three times a day.
Label section 2.4: Starting dose for patients taking methylphenidate two or three times daily at 10–60 mg/day (same steps as the Concerta table).
| Current methylphenidate | Relexxii starting dose |
|---|---|
| 5 mg two or three times daily | 18 mg once daily in the morning |
| 10 mg two or three times daily | 36 mg once daily in the morning |
| 15 mg two or three times daily | 54 mg once daily in the morning |
| 20 mg two or three times daily | 72 mg once daily in the morning |
Amphetamines
Vyvanse · Prescribing Information, revised 04/2026
Vyvanse capsules and chewables can be swapped at the same strength.
Label section 2.2: Vyvanse capsules and chewable tablets can be substituted unit-per-unit and mg-per-mg (for example, a 30 mg capsule for a 30 mg chewable tablet).
Adderall XR · Prescribing Information, revised 04/2026
From Adderall tablets taken in divided doses, the label allows the same total daily amount as one Adderall XR dose.
Label section 2.2: Based on bioequivalence data, patients taking divided doses of immediate-release Adderall (for example, twice daily) may be switched to Adderall XR at the same total daily dose once daily, then titrated weekly.
From other medicines, Adderall XR starts at the usual starting dose.
Label section 2.3–2.5: Patients switching from another medication start like new patients: 10 mg/day (ages 6–17) or 20 mg/day (adults).
Xelstrym · Prescribing Information, revised 09/2025
Dose is worked out again from the start.
Label section 2.4: From another medication or any other amphetamine product: stop and titrate; do not substitute milligram-for-milligram.
Mydayis · Prescribing Information, revised 04/2026
Dose is worked out again from the start.
Label section 2.7: From another medication or any other amphetamine product: stop and titrate; do not substitute milligram-for-milligram (different amphetamine base compositions and pharmacokinetics).
Adzenys XR-ODT · Prescribing Information, revised 09/2025
The label lists which Adzenys XR-ODT strength matches each Adderall XR capsule.
Label section 2.5: Patients taking Adderall XR may switch to the equivalent Adzenys XR-ODT dose once daily (label Table 1). From any other amphetamine product: stop and titrate; do not substitute milligram-for-milligram.
| Adderall XR | Adzenys XR-ODT (equivalent dose) |
|---|---|
| 5 mg | 3.1 mg |
| 10 mg | 6.3 mg |
| 15 mg | 9.4 mg |
| 20 mg | 12.5 mg |
| 25 mg | 15.7 mg |
| 30 mg | 18.8 mg |
Nonstimulants
Intuniv · Prescribing Information, revised 06/2025
From short-acting guanfacine, the dose is worked out again.
Label section 2.3: From immediate-release guanfacine: stop and titrate; do not substitute milligram-for-milligram (differing pharmacokinetics).
Kapvay · Prescribing Information, revised 10/2025
Other clonidine products are not swapped at the same dose.
Label section 2.1: Substituting clonidine ER tablets for other clonidine products mg-per-mg is not recommended (no controlled trial data; differing pharmacokinetics).
Onyda XR · Prescribing Information, revised 04/2025
From other clonidine products, the dose is worked out again.
Label section 2.3: From another clonidine product: stop and titrate; do not substitute milligram-for-milligram (differing pharmacokinetics).
Atoncy · Prescribing Information, SPL version 1, effective Apr 2, 2026
Atoncy is atomoxetine as a liquid; the label reports it behaves like atomoxetine capsules in the body.
Label section 12.3: No clinically significant pharmacokinetic differences were seen between Atoncy and immediate-release atomoxetine capsules under fasted conditions; dosing is stated in the same mg and mg/kg terms. The label does not give a separate switching instruction.
Cross-class conversions (approximate)
This guide does not list approximate methylphenidate-to-amphetamine or stimulant-to-nonstimulant dose equivalents. No FDA label gives one, and no published review with such a conversion has been verified for this site yet. A prescriber choosing a starting dose after a cross-class switch uses the new product’s label starting dose and titration.
Research: trying the other stimulant family (outside the labels)
The labels do not say what to do if one stimulant family does not work or is not tolerated. Small studies suggest that people often respond differently to amphetamine and methylphenidate, so trying the other family can help. Talk to your prescriber before any change.
In a randomized crossover trial, 36 medication-naive children aged 9–14 took methylphenidate, dextroamphetamine and placebo for 2 weeks each; each stimulant gave a favourable response in 26 (72%), and trying both raised favourable responders to 33 (92%) (Ramtvedt 2013; PubMed 23659360). In a naturalistic cohort of 49 unmedicated adults, 41% switched stimulant family within 90 days because of poor tolerability, more often after starting methylphenidate; baseline features did not predict switching (Biederman 2021; PubMed 33657069). Neither study tested a dose-conversion method.
Research: switching to atomoxetine (outside the labels)
The labels do not say how fast to switch from a stimulant to atomoxetine. Two studies compared different ways of crossing over. Talk to your prescriber before any change. Atomoxetine is not FDA-approved for children under 6.
In a randomized trial of 111 patients, a stimulant was cross-titrated to atomoxetine over 2 weeks (fast) or 10 weeks (slow); there were no clinically relevant differences (ADHD-RS change after 2 weeks −8.1 vs −8.0, p=0.927; after 10 weeks −15.0 vs −14.3, p=0.692) (Cardo 2013; PubMed 23683140). In a pilot of 62 children and adolescents crossing from methylphenidate or amphetamine to atomoxetine, mean heart rate rose 9.2 bpm (Quintana 2007; PubMed 17692731). Neither study is a dose-conversion table. Observational preschool data comparing an alpha-2 agonist with a stimulant (Harstad 2021, n=497, not FDA-approved under 6; PubMed 33946100) are summarized on the nonstimulants page; they do not describe a switch protocol.
Labels with no switching statement
Section 2 of these labels gives no switching or conversion instruction (checked Oct 29, 2026): Aptensio XR, Cotempla XR-ODT, Qelbree, Simtriyo (Section 2.4 covers only starting after an MAOI.), Strattera (atomoxetine) (Section 2.6 covers only the 14-day gap when switching to or from an MAOI antidepressant.), Ritalin, Adderall (The label (no revision date shown on DailyMed) lists the amphetamine base content of each tablet strength but gives no switching instruction.), Evekeo, Metadate CD, Arynta, Zenzedi, ProCentra, Dexedrine Spansule, Methylin, Evekeo ODT (Discontinued; no current DailyMed label (Drugs@FDA label used on its page).), Desoxyn, Methylphenidate ER (10/20 mg), Methylphenidate Chewable.
Sources
Each product’s current FDA prescribing information, section 2 (Dosage and Administration; Atoncy: section 12.3), as linked beside each entry. Labels read from DailyMed on Oct 29, 2026.